Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes: a Case Study

[Electronic Supplementary Material]

Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes: A case study

Miyako Kishimoto, Mitsuhiko Noda

Figure legends

Figure 2

Hormonal changes in case 1.

Time course of plasma glucose (A), serum C-peptide (B), plasma glucagon (C), total glucagon-like peptide-1 (GLP-1) (D), active GLP-1 (E), total glucose-dependent insulinotropic polypeptide (GIP) (F), and active GIP (G) levels before and after a meal in case 1. The clear squares indicate insulin, filled squares indicate miglitol administration in addition to insulin treatment, and filled triangles indicate coadministration of miglitol and sitagliptin in addition to insulin treatment.

Figure 3

Hormonal changes in case 2.

Time course of plasma glucose (A), serum C-peptide (B), plasma glucagon (C), total glucagon-like peptide-1 (GLP-1) (D), active GLP-1 (E), total glucose-dependent

insulinotropic polypeptide (GIP) (F), and active GIP (G) levels before and after a meal in case 2.

Figure 4

Hormonal changes in case 3.

Time course of plasma glucose (A), serum C-peptide (B), plasma glucagon (C), total glucagon-like peptide-1 (GLP-1) (D), active GLP-1 (E), total glucose-dependent insulinotropic polypeptide (GIP) (F), and active GIP (G) levels before and after a meal in case 3.

Figure 5

Hormonal changes in case 4.

Time course of plasma glucose (A), serum C-peptide (B), plasma glucagon (C), total glucagon-like peptide-1 (GLP-1) (D), active GLP-1 (E), total glucose-dependent insulinotropic polypeptide (GIP) (F), and active GIP (G) levels before and after a meal in case 4.

Figure 6

Active:total glucagon-like peptide-1 (GLP-1) ratio

Time course of active:total GLP-1 ratio in case 1 (A), case 2 (B), case 3 (C), and case 4 (D) with coadministration of miglitol and anagliptin in addition to ongoing insulin treatment.

Figure 7

Active:total glucose-dependent insulinotropic polypeptide (GIP) ratio

Time course of active:total GIP ratio in case 1 (A), case 2 (B), case 3 (C), and case 4 (D) with the coadministration of miglitol and anagliptin in addition to ongoing insulin treatment.